Aptar's Bidose Nasal System Delivers CARDAMYST™ (etripamil), the First and Only Self-Administered FDA-Approved Nasal Spray for Paroxysmal Supraventricular Tachycardia (PSVT)

Core Viewpoint - Aptar Group, Inc. has announced that its Bidose Liquid Nasal Spray System will be used for the newly approved CARDAMYST Nasal Spray, which is intended for treating acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) [1] Company Summary - Aptar Group, Inc. is recognized as a global leader in drug and consumer product dosing, dispensing, and protection technologies [1] - The Bidose Liquid Nasal Spray System is a key product in Aptar's portfolio, showcasing its capabilities in drug delivery systems [1] Industry Summary - The approval of CARDAMYST by the U.S. Food and Drug Administration (FDA) highlights advancements in treatment options for PSVT, indicating a growing market for innovative drug delivery systems [1]